P2RY11

P2Y purinoceptor 11 · Q96G91 · P2RY11 on Sugi Atlas →

14,295 patent compounds predicted against P2RY11, 11,363 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Suramin (SCHEMBL3161)	1.00	9/20
Suramin (SCHEMBL414636)	0.84	9/20
SCHEMBL375471	0.80	6/20
SCHEMBL849412	0.76	5/20
Fludarabine Phosphate (SCHEMBL3511)	0.73	5/20
Fludarabine Phosphate (SCHEMBL482449)	0.73	5/20
Fludarabine Phosphate (SCHEMBL899922)	0.73	5/20
Fludarabine Phosphate (SCHEMBL1650192)	0.73	5/20
SCHEMBL636959	0.73	4/20
SCHEMBL375601	1.00	3/20
SCHEMBL375602	1.00	3/20
SCHEMBL195864	0.98	3/20
SCHEMBL195865	0.98	3/20
Adenosine Phosphate (SCHEMBL1416760)	0.83	3/20
Adenosine Phosphate (SCHEMBL145417)	0.83	3/20
Adenosine Phosphate (SCHEMBL353218)	0.83	3/20
Adenosine Phosphate (SCHEMBL1356934)	0.83	3/20
Adenosine Phosphate (SCHEMBL1164224)	0.81	3/20
Adenosine Phosphate (SCHEMBL1164292)	0.81	3/20
Adenosine Triphosphate (SCHEMBL193646)	0.80	3/20

Clinical trials — most relevant to P2RY11 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel	PHASE4	COMPLETED
Add-on Cangrelor in STEMI-triggered Cardiac Arrest	PHASE4	UNKNOWN
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine	PHASE4	COMPLETED
Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI	PHASE4	COMPLETED
Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study	PHASE4	COMPLETED
Reversal of the Anti-platelet Effects of Ticagrelor	PHASE4	COMPLETED
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR	PHASE4	NOT_YET_RECRUITING
Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease	PHASE4	COMPLETED
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study	PHASE4	COMPLETED
OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial	PHASE4	COMPLETED
The Effect of IV Cangrelor and Oral Ticagrelor Study	PHASE4	COMPLETED
PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment	PHASE4	COMPLETED
Clopidogrel and Response Variability Investigation Study 2	PHASE3	COMPLETED
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease	PHASE2/PHASE3	COMPLETED
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.	PHASE3	WITHDRAWN
Trimetazidine as an Adjunct to Enhance Clopidogrel Response.	PHASE2	COMPLETED
Ticagrelor and Intracoronary Morphine in Patients Undergoing Primary Percutaneous Coronary Intervention	PHASE2	UNKNOWN
POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy	PHASE2	RECRUITING
Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects	PHASE1	COMPLETED
Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults	EARLY_PHASE1	COMPLETED
A Genomic Approach for Clopidogrel in Caribbean Hispanics	EARLY_PHASE1	COMPLETED
Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence	nan	COMPLETED
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)	nan	ACTIVE_NOT_RECRUITING
Platelet Function in Resuscitated Patients	nan	COMPLETED
Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention	nan	COMPLETED
Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders	nan	UNKNOWN
Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES	nan	UNKNOWN
Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor	nan	COMPLETED
Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes	nan	COMPLETED
Potential Effect of Acute and Chronic Caffeine Administration on Platelet Reactivity in Patient With Coronary Artery Disease on Dual Antiplatelet Therapy	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a P2RY11 binder may also engage these)

Protein	Name	Similarity
Q920E0	—	0.990	Q920E0 →
LPAR5	Lysophosphatidic acid receptor 5	0.985	landscape →
Q3ZC80	—	0.984	Q3ZC80 →
Q149R9	—	0.982	Q149R9 →
Q76JU9	—	0.981	Q76JU9 →
Q8K3T4	—	0.981	Q8K3T4 →
O88634	—	0.980	O88634 →
OXER1	Oxoeicosanoid receptor 1	0.975	landscape →
P34997	—	0.975	P34997 →
GPR17	Uracil nucleotide/cysteinyl leukotriene receptor	0.974	landscape →
FFAR1	Free fatty acid receptor 1	0.973	landscape →
O00270	—	0.973	O00270 →
Q6NS65	—	0.973	Q6NS65 →
RXFP4	Relaxin-3 receptor 2	0.972	landscape →
Q9GLX0	—	0.972	Q9GLX0 →
Q76JU8	—	0.972	Q76JU8 →
F2RL3	Proteinase-activated receptor 4	0.972	landscape →
Q09QM4	—	0.971	Q09QM4 →
PTGDR2	Prostaglandin D2 receptor 2	0.971	landscape →
GALR2	Galanin receptor type 2	0.971	landscape →
P0C5I1	—	0.971	P0C5I1 →
Q04683	—	0.970	Q04683 →
A0A6I8PUB9	—	0.970	A0A6I8PUB9 →
Q76JV1	—	0.970	Q76JV1 →
CCRL2	C-C chemokine receptor-like 2	0.969	landscape →
P43142	—	0.969	P43142 →
O15218	—	0.968	O15218 →
Q863H8	—	0.968	Q863H8 →
P31392	—	0.968	P31392 →
Q8BW93	—	0.968	Q8BW93 →